<DOC>
	<DOCNO>NCT00833703</DOCNO>
	<brief_summary>This study extension CLARINET study [ NCT00396877 -EFC5314 ] neonates infant cyanotic congenital heart disease palliate systemic-to-pulmonary artery shunt . The primary objective ass safety 18 month age extend use Clopidogrel 0.2 mg/kg/day patient shunt still place one year age . The secondary objective ass efficacy occurrence shunt thrombosis require intervention death .</brief_summary>
	<brief_title>Long Term Safety Clopidogrel Neonates/Infants With Systemic Pulmonary Artery Shunt Palliation</brief_title>
	<detailed_description>Patients remain treatment group originally allocate CLARINET study continue blindly treatment ( 0.2 mg/kg/day clopidogrel placebo ) occurrence shunt thrombosis , next surgical procedure correction congenital heart disease , death , 18 month age , whichever come first . The maximum treatment duration 6 month .</detailed_description>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Patients randomize CLARINET study , Still receive study drug , Palliative systemictopulmonary artery shunt still place 1 year age , Investigator 's decision continue base his/her judgment expect benefit / risk continue treatment study drug , Signed inform consent participate longterm safety study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>cyanotic congenital heart disease</keyword>
	<keyword>shunt palliation</keyword>
	<keyword>thrombosis</keyword>
	<keyword>clopidogrel</keyword>
</DOC>